InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), will be featured at the upcoming VirtualInvestorConferences.com. InMed president and CEO is scheduled to present a real-time, interactive presentations during the two-day conference; InMed’s presentation will start at 1:30 p.m. ET on Sept. 8, 2021. During the presentation Adams will provide an overview of the company’s recent highlights as well as answer questions from potential investors in real time. Company highlights include the announcement that it has increased the yield of its proprietary IntegraSyn(TM) rare cannabinoid manufacturing approach to 5 g/L, further improving the overall economics in advance of commercial-scale production and that it has signed a nonbinding letter of intent to acquire BayMedica, a private company that specializes in the manufacture and commercialization of rare cannabinoids. In addition, as part of a phase 2 clinical trial, InMed has filed clinical trial applications in several countries. Virtual Investor Conferences (“VIC”) has developed a reputation for being a leading proprietary investor conference series; VIC events provide an interactive forum for publicly traded companies to meet and present directly with investors.
To register for the event, visit https://ibn.fm/0HHBZ
To view the full press release, visit https://ibn.fm/gYYIo
About InMed Pharmaceuticals Inc.
InMed is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”) and is developing IntegraSyn to produce pharmaceutical-grade cannabinoids. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.